|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blanchard P, Baujat B, Holostenco V,
Bourredjem A, Baey C, Bourhis J and Pignon JP; MACH-CH
Collaborative group: Meta-analysis of chemotherapy in head and neck
cancer (MACH-NC): A comprehensive analysis by tumour site.
Radiother Oncol. 100:33–40. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marur S and Forastiere AA: Head and neck
squamous cell carcinoma: Update on epidemiology, diagnosis, and
treatment. Mayo Clin Proc. 91:386–396. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dauzier E, Lacas B, Blanchard P, Le QT,
Simon C, Wolf G, Janot F, Horiuchi M, Tobias JS, Moon J, et al:
Role of chemo-therapy in 5000 patients with head and neck cancer
treated by curative surgery: A subgroup analysis of the
meta-analysis of chemotherapy in head and neck cancer. Oral Oncol.
95:106–114. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alsahafi E, Begg K, Amelio I, Raulf N,
Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and
neck cancer: Molecular biology and ongoing challenges. Cell Death
Dis. 10:5402019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pendleton KP and Grandis JR:
Cisplatin-based chemotherapy options for recurrent and/or
metastatic squamous cell cancer of the head and neck. Clin Med
Insights Ther. 2013: View Article : Google Scholar : 2013.PubMed/NCBI
|
|
8
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Furqan M, Snyders TP, Saqlain MU, Mott SL,
Laux D, Snow A, Anderson CM, Watkins JM and Clamon GH: Comparing
high-dose cisplatin with cisplatin-based combination chemo-therapy
in definitive concurrent chemoradiation setting for locally
advanced head and neck squamous cell carcinoma (LAHNSCC). Cancer
Med. 8:2730–2739. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar
|
|
12
|
Towne TG and Murray A: Encyclopedia of
Toxicology. 3rd edition. Academic Press; 2014
|
|
13
|
Pratt WB and Ruddon RW: The anticancer
drugs. Oxford University Press; 1979
|
|
14
|
Makovec T: Cisplatin and beyond: Molecular
mechanisms of action and drug resistance development in cancer
chemotherapy. Radiol Oncol. 53:148–158. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamano Y, Uzawa K, Saito K, Nakashima D,
Kasamatsu A, Koike H, Kouzu Y, Shinozuka K, Nakatani K, Negoro K,
et al: Identification of cisplatin-resistance related genes in head
and neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010.
View Article : Google Scholar
|
|
16
|
Marur S and Forastiere AA: Head and neck
cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin
Proc. 83:489–501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
American Cancer Society: Global cancer
facts and figures 2018. Atlanta; American Cancer Society; 2018
|
|
18
|
Cho H, Nishiike S, Yamamoto Y, Takenaka Y,
Nakahara S, Yasui T, Hanamoto A and Inohara H: Docetaxel,
Cisplatin, and fluorouracil for patients with inoperable recurrent
or metastatic head and neck squamous cell carcinoma. Auris Nasus
Larynx. 42:396–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lorch J, Goloubeva O, Haddad R, Cullen K,
Sarlis N, Tishler R, Tan M, Fasciano J and Sammartino DE: Induction
chemotherapy with Cisplatin and fluorouracil alone or in
combination with docetaxel in locally advanced squamous-cell cancer
of the head and neck: Long-term results of the TAX 324 randomized
phase 3 trial. Lancet Oncol. 12:153–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Porceddu SV, Scotté F, Aapro M, Salmio S,
Castro A, Launay-Vacher V and Licitra L: treating patients with
locally advanced squamous cell carcinoma of the head and neck
unsuitable to receive cisplatin-based therapy. Front Oncol.
9:15222020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szturz P, Cristina V, Herrera Gómez RG,
Bourhis J, Simon C and Vermorken JB: Cisplatin eligibility issues
and alternative regimens in locoregionally advanced head and neck
cancer: Recommendations for clinical practice. Front Oncol.
9:4642019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng H, Chen L, Li WF, Guo R, Mao YP,
Zhang Y, Zhang F, Liu LZ, Tian L, Lin AH, et al: The cumulative
cisplatin dose affects the long-term survival outcomes of patients
with nasopharyngeal carcinoma receiving concurrent
chemoradiotherapy. Sci Rep. 6:243322016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Le X and Hanna EY: Optimal regimen of
cisplatin in squamous cell carcinoma of head and neck yet to be
determined. Ann Transl Med. 6:2292018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Strojan P, Vermorken JB, Beitler JJ, Saba
NF, Haigentz M Jr, Bossi P, Worden FP, Langendijk JA, Eisbruch A,
Mendenhall WM, et al: Cumulative cisplatin dose in concurrent
chemoradiotherapy for head and neck cancer: A systematic review.
Head Neck. 38(Suppl 1): E2151–E2158. 2016. View Article : Google Scholar
|
|
25
|
Szturz P, Wouters K, Kiyota N, Tahara M,
Prabhash K, Noronha V, Adelstein D, Van Gestel D and Vermorken JB:
Low-dose vs. High-dose cisplatin: Lessons learned from 59
chemoradiotherapy trials in head and neck cancer. Front Oncol.
9:862019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mashhour K and Hashem W: Cisplatin weekly
versus every 3 weeks concurrently with radiotherapy in the
treatment of locally advanced head and neck squamous cell
carcinomas: What is the best dosing and schedule? Asian Pac J
Cancer Prev. 21:799–807. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nouman M, Haider G, Bukhari N, Yousuf A,
Nouman R, Shaikh MR, Hussain S, Pavan B, Rahool R, Memon P, et al:
Response rate of cisplatin plus docetaxel as primary treatment in
locally advanced head and neck carcinoma (squamous cell types).
Asian Pac J Cancer Prev. 21:825–830. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duan X, He C, Kron SJ and Lin W:
Nanoparticle formulations of cisplatin for cancer therapy. Wiley
Interdiscip Rev Nanomed Nanobiotechnol. 8:776–791. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kayyali MN, Ramsey AJ, Higbee-Dempsey EM,
Yan L, O'Malley BW Jr, Tsourkas A and Li D: The development of a
nano-based approach to alleviate cisplatin-induced ototoxicity. J
Assoc Res Otolaryngol. 19:123–132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mehtala JG, Torregrosa-Allen S, Elzey BD,
Jeon M, Kim C and Wei A: Synergistic effects of cisplatin
chemotherapy and gold nanorod-mediated hyperthermia on ovarian
cancer cells and tumors. Nanomedicine (Lond). 9:1939–1955. 2014.
View Article : Google Scholar
|
|
31
|
Miao L, Guo S, Zhang J, Kim WY and Huang
L: Nanoparticles with precise ratiometric co-loading and
co-delivery of gemcitabine monophosphate and cisplatin for
treatment of bladder cancer. Adv Funct Mater. 24:6601–6611. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miao L, Wang Y, Lin CM, Xiong Y, Chen N,
Zhang L, Kim WY and Huang L: Nanoparticle modulation of the tumor
microen-vironment enhances therapeutic efficacy of cisplatin. J
Control Release. 217:27–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Green HN, Martyshkin DV, Rosenthal EL and
Mirov SB: A minimally invasive multifunctional nanoscale system for
selective targeting, imaging, and NIR photothermal therapy of
malignant tumors. In: Proceedings of the Reporters, Markers, Dyes,
Nanoparticles, and Molecular Probes for Biomedical Applications
III; 7910. SPIE BiOS; San Francisco, CA. 2011
|
|
34
|
Green HN, Crockett SD, Martyshkin DV,
Singh KP, Grizzle WE, Rosenthal EL and Mirov SB: A histological
evaluation and in vivo assessment of intratumoral near infrared
photothermal nanotherapy-induced tumor regression. Int J
Nanomedicine. 9:5093–5102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sebaugh JL: Guidelines for accurate
EC50/IC50 estimation. Pharm Stat. 10:128–134. 2011. View Article : Google Scholar
|
|
36
|
Guo S, Lin CM, Xu Z, Miao L, Wang Y and
Huang L: Co-delivery of cisplatin and rapamycin for enhanced
anticancer therapy through synergistic effects and microenvironment
modulation. ACS Nano. 8:4996–5009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou F, Feng B, Yu H, Wang D, Wang T, Liu
J, Meng Q, Wang S, Zhang P, Zhang Z and Li Y: Cisplatin
prodrug-conjugated gold nanocluster for fluorescence imaging and
targeted therapy of the breast cancer. Theranostics. 6:679–687.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hackenberg S, Scherzed A, Harnisch W,
Froelich K, Ginzkey C, Koehler C, Hagen R and Kleinsasser N:
Antitumor activity of photo-stimulated zinc oxide nanoparticles
combined with paclitaxel or cisplatin in HNSCC cell lines. J
Photochem Photobiol B. 114:87–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hackenberg S, Scherzed A, Kessler M,
Froelich K, Ginzkey C, Koehler C, Burghartz M, Hagen R and
Kleinsasser N: Zinc oxide nanoparticles induce photocatalytic cell
death in human head and neck squamous cell carcinoma cell lines in
vitro. Int J Oncol. 37:1583–1590. 2010.PubMed/NCBI
|
